MicroPort
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
MicroPort Scientific Corporation (HKG:00853) is a Shanghai-based medical device group founded in 1998 by Chang Zhaohua. Listed on the Hong Kong Stock Exchange in 2010, it grew into one of China's largest medtech companies, spanning cardiovascular intervention (coronary stents, heart valves), orthopaedics, electrophysiology, surgical robotics (Shanghai MicroPort MedBot) and endovascular devices, with expanding overseas sales. The group reported FY2024 revenue of $1.03 billion, up 8.5% year-on-year, but remained loss-making after years of heavy R&D spending, global expansion and acquisition-driven growth. Its 2024 annual results reported a net loss of $268.5 million for the year - a sharp improvement from the $649.2 million loss in 2023, driven by cost optimization, resource concentration and revenue contributions from new and leading products. The interim H1 2024 results showed a 41% decrease in attributable loss versus H1 2023. Management later guided to at least $20 million of net profit for 2025, signaling an attempted turnaround.
02 / MicroPort FAILURE REASONS
Failure reasons
MicroPort's failure is the classic 'growth at any cost' story playing out on a public company's income statement. After listing in 2010, it chased global scale - heavy annual R&D investment, overseas expansion, and a portfolio of capital-intensive subsidiaries (robotics, electrophysiology, valves) - financed in part by debt and convertible bonds. The bill came due from 2020: the group posted five consecutive years of net losses, peaking at $649 million in 2023, as R&D costs, distribution costs and impairment losses on non-current assets overwhelmed a still-growing revenue line, and cash reserves fell 30% in a single year. The 2024 result - a $268.5 million loss - was 'reported' as the bottoming event: losses had narrowed sharply, but the cumulative damage (five years of deep losses, diluted shareholders, a stretched balance sheet) was the cost of the expansion strategy. The turnaround now depends on whether commercialization of its leading products can sustainably cover a cost base built for a much larger company.
03 / EVENT HISTORY
Events in the structured record
- Founded
Chang Zhaohua founded MicroPort Scientific in Shanghai as a medical device company.
- Listed
MicroPort listed on the Hong Kong Stock Exchange (00853), growing into a diversified medtech group with global expansion.
- Losses begin
The group entered a five-year stretch of net losses as R&D, global expansion and impairments overwhelmed revenue growth.
- Loss bottoming
FY2024 revenue grew 8.5% to $1.03 billion while the net loss narrowed sharply to $268.5 million from $649.2 million in 2023; management guided to a 2025 return to profitability.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Reported a net loss of US$268.5 million for FY2024 on revenue of about US$1.03 billion (+8.5%), narrowing sharply from a US$649.2 million loss in 2023.
- 02
The company guided for at least US$20 million of net profit in 2025, framing the narrower loss as a turn toward profitability.
- 03
No insolvency or restructuring was announced; MicroPort Scientific Corporation remains listed and operating.